Sanofi (NASDAQ:SNY) Upgraded at StockNews.com

StockNews.com upgraded shares of Sanofi (NASDAQ:SNY) from a buy rating to a strong-buy rating in a research report report published on Wednesday morning.

Several other equities research analysts have also recently commented on the company. Argus boosted their price target on Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Citigroup raised Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. Two equities research analysts have rated the stock with a hold rating, one has given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $57.50.

Sanofi Trading Up 0.7 %

NASDAQ:SNY opened at $53.27 on Wednesday. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. Sanofi has a fifty-two week low of $45.00 and a fifty-two week high of $58.97. The stock’s 50-day moving average is $55.92 and its two-hundred day moving average is $51.96. The stock has a market cap of $135.19 billion, a PE ratio of 27.18, a price-to-earnings-growth ratio of 1.35 and a beta of 0.61.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Friday, October 25th. The company reported $1.57 EPS for the quarter, beating the consensus estimate of $0.22 by $1.35. The business had revenue of $13.44 billion during the quarter, compared to analysts’ expectations of $16.59 billion. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The firm’s quarterly revenue was up 12.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.55 EPS. As a group, equities research analysts forecast that Sanofi will post 4.27 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sanofi

A number of large investors have recently added to or reduced their stakes in SNY. POM Investment Strategies LLC bought a new stake in Sanofi during the second quarter worth approximately $25,000. Larson Financial Group LLC boosted its position in Sanofi by 480.8% during the first quarter. Larson Financial Group LLC now owns 604 shares of the company’s stock worth $29,000 after purchasing an additional 500 shares during the period. Northwest Investment Counselors LLC bought a new stake in Sanofi during the third quarter worth approximately $29,000. Palisade Asset Management LLC bought a new stake in Sanofi during the first quarter worth approximately $31,000. Finally, Concord Wealth Partners boosted its position in shares of Sanofi by 157.8% in the third quarter. Concord Wealth Partners now owns 593 shares of the company’s stock valued at $34,000 after acquiring an additional 363 shares during the period. Institutional investors own 10.04% of the company’s stock.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.